Navigation Links
VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo
Date:4/20/2009

MMPSense(TM) 750 FAST is Presented at AACR 100th Annual Meeting

BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the introduction of its new FAST ("Fluorescent Activatible Sensor Technology") imaging agent platform for advanced imaging of key disease-associated biomarkers and drug response in vivo. Newly developed by VisEn Medical, FAST imaging agents are smaller molecule, biocompatible, activatible fluorescent agents that combine increased biomarker specificity with accelerated pharmacokinetics for advanced measurement and monitoring of key disease biomarkers in vivo. The new MMPSense 750 FAST, the first of the FAST agents to be launched by VisEn, was described today in a scientific poster presentation entitled "In vivo imaging of treatment effects using a novel near-infrared labeled agent: MMPSense 750 FAST", at the annual Scientific Sessions of the AACR (American Association of Cancer Research) 100th Annual Meeting 2009 in Denver, CO by Jeffrey D. Peterson, Ph.D., Vice President of Applied Biology at VisEn.

At the AACR 100th Annual Meeting, the Peterson et al study demonstrated the performance of MMPSense 750 FAST as a fast-acting, near-infrared imaging agent to measure tumor MMP activity in vivo and monitor treatment efficacy. In the study, administration of the agent allowed the non-invasive measurement of MMP inhibition using two different chemotherapy regimes. Using the VisEn FMT 2500(TM) quantitative tomography system, tumor fluorescence due to in vivo activation of the agent was clearly detectable as early as 4 hours after injection of the agent with the signal maximizing between 6 and 24 hours. By 96 hours, only 15% of the signal was still present in tumors. "Our study utilized MMPSense 750 FAST as a mechani
'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent
2. VisEn Medical Raises $7 Million in Series B Financing
3. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
4. Cell Biosciences Launches Next-Generation Protein Characterization System
5. Accera, Inc. Launches Neuera Pharmaceuticals, Inc.
6. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
7. US Oncology Launches New Web Site
8. Pharmaceutical Institute Launches New Training Series Focused on Managed Markets Excellence
9. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
10. Selexis Launches Biosimilar Cell Line Development Program
11. First Application to Fight High Cholesterol Launches on the iPhone and iPod Touch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... 2015 , ... Sterlitech Corporation introduces the compact, quiet, and ... laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free design, ... solution for a broad range of vacuum filtration applications. , Featuring a 1/7 ...
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of the ... in Marshall. The Ralco Enrichment Center is an interactive experience where the public can ... lives. This unique exhibit also features a birthing center for fair goers to watch ...
(Date:7/30/2015)... -- According to a new market research ... PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), by ... End Users - Global Forecast to 2020", published by ... 2,107.99 million by 2020 from USD 1,034.93 million in ... Browse more than 75 market ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
Breaking Biology Technology:Sterlitech Launches New Line of Vacuum Pumps 2Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... Mich., July 8 GeneGo, Inc., the leading,systems biology ... GeneGo products. Unilever uses systems analysis tools for,research in ... "Unilever was one of GeneGo,s first customers in Europe, ... said Julie Bryant, GeneGo,s VP,of Business development. "Unilever is ...
... Metabolex, Inc., a,biopharmaceutical company focused on the ... treatment of metabolic diseases,announced that it has promoted ... and Robert Martin to Vice President of Project ... development in our company,in support of our expanding ...
... Md., July 7 ActiPatch(TM), the,product marketed by Bioelectronics ... and the way we heal. Recently chosen as "One ... MedicalHeadway.com,ActiPatch is fast becoming the treatment of choice for ... decision to include ActiPatch in the top 9 medical ...
Cached Biology Technology:Unilever Extends Their GeneGo MetaCore License 2Metabolex Names Zhao, Martin to Executive Posts 2BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 2BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 3BioElectronic's ActiPatch(TM) Product Chosen as 'One of 9 Medical Breakthroughs That May Change Your Life' 4
(Date:7/23/2015)... Inc. (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2015.  Revenue for ... of 33% compared to $6.8 million in the same quarter ... was $0.3 million, or $0.01 per diluted share, which compared ... same period a year ago.  Lower revenue ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
Breaking Biology News(10 mins):Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... and ecological sustainability of biofuels and the impact of ... America will take place on Friday, Dec. 5, in ... Neotropical Forests: Trends, Implications and Emerging Alternatives, is sponsored ... the Program in Native Species Reforestation, both joint programs ...
... Associated Professor, DSc Barbara Ann Halkier, Department of ... Life Sciences, University of Copenhagen, has been granted ... award for her excellent research into secondary metabolites, ... plants. In particular, her research has focused ...
... Company Experiences Record Revenue Growth from Operations in Third Quarter , ... bioMETRX, Inc. (OTC Bulletin Board: BMRX), a leading developer of consumer-based ... ending September 30, 2008. , , ... 430% increase over second quarter revenues of $100,000. , ...
Cached Biology News:Conference to explore sustainability of biofuels 2The Danisco Award 2008 goes to D.Sc. Barbara Ann Halkier from Faculty of Life Sciences, Copenhagen 2bioMETRX, Inc. Highlights 3rd Quarter 2008 Financial Results 2